A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Status:
NOT_YET_RECRUITING
Trial end date:
2028-06-11
Target enrollment:
Participant gender:
Summary
This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively. The cancer types include solid tumors.